Latest news with #Amycretin
Extra.ie
21-06-2025
- Health
- Extra.ie
New weight loss pill set to rival 'fat jab' shows promising results in early trials
A new weight loss treatment that can be taken as either a daily pill or a weekly injection has shown very promising results in initial trials, according to a new study. In one of the tests, 125 adults were assigned weekly injections of a drug called 'AMYCRETIN', and early results showed that those receiving the 60 milligram dose lost nearly a quarter of their body weight over 36 weeks. 'Amycretin' is a 'unimolecular long-acting GLP-1 and amylin receptor agonist' under development by Novo Nordisk, to provide a treatment for adults with obesity and as a treatment for adults with type 2 diabetes. Pic: Shutterstock If the initial results turn out to be effective in the long run, this may make 'Amycretin' a more effective treatment for obesity than other weight loss drugs like Weygovy and Ozempic. Another trial enrolled 144 adults to test the 'pill version' of 'Amycretin'. Those who took the 100 milligram daily tablet lost an average of 13.1 percent of their weight over 12 weeks. Novo-Nordisk, who are heading up the research into this new medication says initial trials suggest Amycretin could be on the market by next year. Pic: Getty Images The strongest prescription weight loss medication currently approved by the FDA is Semaglutide, marketed under brand names like Wegovy and Ozempic (for diabetes, also used off-label for weight loss).
Scottish Sun
21-06-2025
- Health
- Scottish Sun
New ‘Ozempic pill' is better than ‘skinny jabs' and helps you lose weight even faster, study suggests
The new weight loss pill has seen promising results and offers hope to millions WEIGH TO GO New 'Ozempic pill' is better than 'skinny jabs' and helps you lose weight even faster, study suggests Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A NEW 'Ozempic pill' leads to faster weight loss than the popular 'skinny jabs', studies have suggested. The new weight loss medication, which can also be offered by injection, can help patients lose a significant amount of weight. Sign up for Scottish Sun newsletter Sign up 1 The new weight loss pill has seen promising results in early trials Credit: Getty An early study found that patients who received amycretin as a weekly jab lost 24% of their body weight after 36 weeks of treatment. But initial trials assessing a tablet form of the jab saw promising results with patients losing an average 13% of bodyweight in just three months. This suggests the drug leads to greater weight loss than Wegovy, the 'sister jab' of Ozempic. Such treatments have been called transformative by NHS leaders. It's estimated that around 1.5 million Brits currently receive weight loss jabs through specialist weight loss services or private prescriptions. But weight pills offer a new hope to millions looking to lose weight as the injections put additional pressure on an overstretched NHS. However, further clinical trials are needed before the treatment can be made available in the UK. This could take several years and there's no guarantee that regulators will approve the use of the drug. Amycretin, made by Novo Nordisk, contains semaglutide, the same active ingredient as Ozempic and Wegovy and helps control blood sugar and appetite. It targets specific receptors in the body - the GLP-1 and amylin receptors - helping you feel full and stops overeating. An early trial published in The Lancet found that 125 adults taking weekly injections containing higher doses of the drug lost nearly a quarter of their body weight after 36 weeks. It also showed signs of improving blood sugar levels. However, there were some mild to moderate side effects including nausea and vomiting but these were resolved by the end of the treatment. Experts said that the medicine appeared "safe and tolerable" but further studies were needed to fully assess the drug. But a second trial, also published in The Lancet, assessed the drug in tablet form in 144 people. Those taking the highest dose of 100mg lost 13% of their body weight over four months. Weight Loss Jabs - Pros vs Cons The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people who were overweight or obese. "Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen." As with the first trial, there were also some mild to moderate side effects including loss of appetite and similar gastrointestinal issues. It comes as a separate study examined the effects of the weight-loss jab, Wegovy, at higher doses. The researchers found that giving patients 7.2mg of Wegovy once a week led to an average weight loss of 21%, with a third of participants losing 25% of their body weight over 72 weeks. The studies were also presented to the American Diabetes Association's Scientific Sessions in Chicago.
The Irish Sun
21-06-2025
- Health
- The Irish Sun
New ‘Ozempic pill' is better than ‘skinny jabs' and helps you lose weight even faster, study suggests
A NEW 'Ozempic pill' leads to faster weight loss than the popular 'skinny jabs', studies have suggested. The new weight loss medication, which can also be offered by injection, can help patients lose a significant amount of weight. Advertisement 1 The new weight loss pill has seen promising results in early trials Credit: Getty An early study found that patients who received amycretin as a weekly jab lost 24% of their body weight after 36 weeks of treatment. But initial trials assessing a tablet form of the jab saw promising results with patients losing an average 13% of bodyweight in just three months. This suggests the drug leads to greater weight loss than Wegovy, the 'sister jab' of Ozempic. Such treatments have been called transformative by NHS leaders. Advertisement Read more Health news It's estimated that around 1.5 million Brits currently receive weight loss jabs through specialist weight loss services or private prescriptions. But weight pills offer a new hope to millions looking to lose weight as the injections put additional pressure on an overstretched NHS. However, further clinical trials are needed before the treatment can be made available in the UK. This could take several years and there's no guarantee that regulators will approve the use of the drug. Advertisement Most read in Health Amycretin, made by Novo Nordisk, contains semaglutide, the same active ingredient as Ozempic and Wegovy and helps control blood sugar and appetite. It targets specific receptors in the body - the GLP-1 and amylin receptors - helping you feel full and stops overeating. An early trial published in The Lancet found that 125 adults taking weekly injections containing higher doses of the drug lost nearly a quarter of their body weight after 36 weeks. It also showed signs of improving blood sugar levels. Advertisement However, there were some mild to moderate side effects including nausea and vomiting but these were resolved by the end of the treatment. Experts said that the medicine appeared "safe and tolerable" but further studies were needed to fully assess the drug. But a second trial, also published in The Lancet, assessed the drug in tablet form in 144 people. Those taking the highest dose of 100mg lost 13% of their body weight over four months. Advertisement Weight Loss Jabs - Pros vs Cons The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people who were overweight or obese. "Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen." As with the first trial, there were also some mild to moderate side effects including loss of appetite and similar gastrointestinal issues. It comes as a separate study examined the effects of the weight-loss jab, Wegovy, at higher doses. Advertisement The researchers found that giving patients 7.2mg of Wegovy once a week led to an average weight loss of 21%, with a third of participants losing 25% of their body weight over 72 weeks. The studies were also presented to the American Diabetes Association's Scientific Sessions in
Wales Online
21-06-2025
- Health
- Wales Online
The new weight loss pill showing significant results within 12 weeks
The new weight loss pill showing significant results within 12 weeks The weight loss pill has showed promise in new trials with some reporting up to 24% weight loss The experimental drug tests have shown up to 24% weight loss (Image: PA ) An early study has found that a new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight. It has found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Stay informed on the latest health news by signing up to our newsletter here Article continues below Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body - GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. "These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity," the authors wrote. "Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment." The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. "Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen." The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Article continues below Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
South Wales Guardian
21-06-2025
- Health
- South Wales Guardian
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
